BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/12/2026 9:18:15 AM | Browse: 346 | Download: 620
Publication Name World Journal of Diabetes
Manuscript ID 114002
Country China
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Clinical Trials Study
Article Title Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial
Manuscript Source Unsolicited Manuscript
All Author List Xue-Dong An, Guo-Liang Zhang, Yue-Hong Zhang, De Jin, Hang-Yu Ji, Li-Juan Wei, Ya-Lin He, Yan-Lin Zheng, Du-Jun Li, Xing-Wei Wu, Yuan-Bin Li, Jian Zhou, Shao-Jian Tan, Ming-Chang Zhang, Ke Fan, Shan Lu, Jing-Sheng Yu, Yu-Liang Wang, Shao-Jun Chen, Qiu-Hong Liu, Ming Jin, Lie Wu, Feng-Mei Lian and Xiao-Lin Tong
ORCID
Author(s) ORCID Number
Xue-Dong An http://orcid.org/0000-0002-2787-1645
Funding Agency and Grant Number
Funding Agency Grant Number
Science and Technology Innovation Project of Chinese Academy of Traditional Chinese Medicine CI2021A02610
State Key Laboratory of Core Technology in Innovative Chinese Medicine, along with the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine ZYYCXTD-D-202001
Corresponding Author Xiao-Lin Tong, Metabolic Disease Research Institute, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. tongxiaolin@vip.163.com., Beijing 100053, China. tongxiaolin@vip.163.com
Key Words Diabetic retinopathy; Compound danshen dripping pills; Clinical trial; Efficacy; Safety
Core Tip Compound danshen dripping pill (CDDP), an approved treatment for non-proliferative diabetic retinopathy (DR) in China, has demonstrated potential in both preclinical and clinical studies. However, its efficacy for non-proliferative DR (NPDR) has not been validated through large-scale clinical trials. We conducted this randomized, placebo-controlled, double-blind, multicenter study to confirm the therapeutic efficacy and safety of CDDP in NPDR.
Publish Date 2026-03-12 09:18
Citation

An XD, Zhang GL, Zhang YH, Jin D, Ji HY, Wei LJ, He YL, Zheng YL, Li DJ, Wu XW, Li YB, Zhou J, Tan SJ, Zhang MC, Fan K, Lu S, Yu JS, Wang YL, Chen SJ, Liu QH, Jin M, Wu L, Lian FM, Tong XL. Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial. World J Diabetes 2026; 17(3): 114002

URL https://www.wjgnet.com/1948-9358/full/v17/i3/114002.htm
DOI https://dx.doi.org/10.4239/wjd.v17.i3.114002
Full Article (PDF) WJD-17-114002-with-cover.pdf